Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises NeuroNova AB in relation to the merger with Newron Pharmaceuticals S.p.A.
Mandate

Vinge advises NeuroNova AB in relation to the merger with Newron Pharmaceuticals S.p.A.

June 13, 2012

Vinge has advised NeuroNova AB in connection with the merger with Newron Pharmaceuticals S.p.A (”Newron”). NeuroNova AB is a research company within the biotechnology and pharmaceuticals industry which primarily develops therapies for illnesses caused by the death of cells in the central nervous system. Newron is a research company within biotechnology and is listed on the Swiss stock exchange (SIX).

Vinge’s team consisted of, among others, responsible partner Johan Winnerblad and associates Matthias Pannier and Alex Miler.

Related

Vinge advises Carasent in connection with the listing on Nasdaq Stockholm

 Vinge advises Carasent AB (publ) in connection with the listing on Nasdaq Stockholm. The listing is made through a reverse cross-border merger, whereby Carasent AB takes over Carasent ASA, previously listed on Oslo Stock Exchange.
December 09, 2024

Vinge has advised Apotea in connection with its listing on Nasdaq Stockholm

 Vinge has advised Apotea AB (publ) (“Apotea”) in connection with its listing on Nasdaq Stockholm. The prospectus was published on November 26, 2024 and the first day of trading is December 6, 2024.
December 06, 2024

Vinge advises on the sale of Dafo Vehicle

 Vinge has advised Sobro and the other owners in connection with the sale of Dafo Vehicle to the US based United Safety & Survivability Corporation. Dafo Vehicle is a leading supplier of fire detection and suppression systems for vehicles and the acquisition creates a global leader within vehicle safety systems.
December 05, 2024